ALDX vs. XERS, NUVB, AMLX, IMTX, ELVN, TRML, TRVI, IMNM, WVE, and CVAC
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Xeris Biopharma (XERS), Nuvation Bio (NUVB), Amylyx Pharmaceuticals (AMLX), Immatics (IMTX), Enliven Therapeutics (ELVN), Tourmaline Bio (TRML), Trevi Therapeutics (TRVI), Immunome (IMNM), WAVE Life Sciences (WVE), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry.
Aldeyra Therapeutics vs. Its Competitors
Xeris Biopharma (NASDAQ:XERS) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.
Xeris Biopharma presently has a consensus target price of $7.08, suggesting a potential downside of 22.71%. Aldeyra Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 72.88%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Xeris Biopharma.
Xeris Biopharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.
Xeris Biopharma has higher revenue and earnings than Aldeyra Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -13.01%. Xeris Biopharma's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.
In the previous week, Xeris Biopharma had 6 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 6 mentions for Xeris Biopharma and 0 mentions for Aldeyra Therapeutics. Xeris Biopharma's average media sentiment score of 0.81 beat Aldeyra Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by insiders. Comparatively, 9.6% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Xeris Biopharma beats Aldeyra Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALDX) was last updated on 10/21/2025 by MarketBeat.com Staff
Free ALDX Stock Alerts